Cytokinetics (CYTK) Insider Trading & Ownership $35.25 +0.11 (+0.31%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$36.74 +1.49 (+4.21%) As of 08:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Cytokinetics (NASDAQ:CYTK) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.70%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)9Amount OfInsider Selling(Last 12 Months)$11.08M Get CYTK Insider Trade Alerts Want to know when executives and insiders are buying or selling Cytokinetics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CYTK Insider Buying and Selling by Quarter Cytokinetics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/5/2025Fady Ibraham MalikEVPSell2,000$36.34$72,680.00 7/29/2025Robert I BlumCEOSell5,000$36.45$182,250.00 7/22/2025Fady Ibraham MalikEVPSell2,000$37.47$74,940.00 7/14/2025Robert I BlumCEOSell5,000$38.15$190,750.00 7/8/2025Fady Ibraham MalikEVPSell2,000$33.76$67,520.00 6/16/2025Robert I BlumCEOSell5,000$33.80$169,000.00 6/5/2025Andrew CallosEVPSell8,659$32.04$277,434.36 6/5/2025Edward M Md KayeDirectorSell3,636$32.10$116,715.60 6/2/2025Robert I BlumCEOSell5,000$31.22$156,100.00 5/15/2025Muna BhanjiDirectorSell1,454$29.73$43,227.42 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 5/5/2025Andrew CallosEVPSell4,002$36.68$146,793.36 4/29/2025Robert I BlumCEOSell5,000$40.96$204,800.00 4/22/2025Fady Ibraham MalikEVPSell2,000$38.11$76,220.00 4/21/2025Wendall WierengaDirectorSell20,000$38.46$769,200.00 4/15/2025John T HendersonDirectorSell3,190$38.66$123,325.40 4/10/2025Robert I BlumCEOSell5,000$36.77$183,850.00 4/7/2025Andrew CallosEVPSell2,886$35.78$103,261.08 4/3/2025Robert Arthur HarringtonDirectorSell450$39.43$17,743.50 3/31/2025Robert I BlumCEOSell15,000$40.75$611,250.00 3/17/2025Andrew CallosEVPSell2,775$44.38$123,154.50 3/17/2025Robert I BlumCEOSell12,648$44.38$561,318.24 3/14/2025Andrew CallosEVPSell100$45.00$4,500.00 3/6/2025Andrew CallosEVPSell3,341$43.27$144,565.07 3/6/2025Robert I BlumCEOSell16,970$43.44$737,176.80 2/18/2025Fady Ibraham MalikEVPSell2,000$45.98$91,960.00 2/4/2025Fady Ibraham MalikEVPSell2,000$48.06$96,120.00 1/21/2025Fady Ibraham MalikEVPSell2,000$45.92$91,840.00 1/7/2025Fady Ibraham MalikEVPSell2,000$49.32$98,640.00 12/16/2024Wendall WierengaDirectorSell742$48.61$36,068.62 12/11/2024John T HendersonDirectorSell1,780$50.42$89,747.60 12/10/2024Fady Ibraham MalikEVPSell7,300$50.64$369,672.00 12/2/2024Robert I BlumCEOSell5,000$50.76$253,800.00 11/26/2024Fady Ibraham MalikEVPSell7,300$50.16$366,168.00 11/18/2024Robert I BlumCEOSell5,000$50.55$252,750.00 11/12/2024Fady Ibraham MalikEVPSell6,342$58.48$370,880.16 11/1/2024Robert I BlumCEOSell5,000$51.63$258,150.00 10/30/2024Fady Ibraham MalikEVPSell7,300$51.91$378,943.00 10/28/2024Wendall WierengaDirectorSell4,452$52.25$232,617.00 10/15/2024Fady Ibraham MalikEVPSell7,300$54.19$395,587.00 10/9/2024Robert I BlumCEOSell5,000$55.61$278,050.00 Trump’s national nightmare is here (Ad)Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.Watch the National Emergency broadcast here10/1/2024Fady Ibraham MalikEVPSell7,300$52.10$380,330.00 9/30/2024Robert I BlumCEOSell5,000$52.14$260,700.00 9/3/2024Fady Ibraham MalikEVPSell7,384$57.01$420,961.84 9/3/2024Robert I BlumCEOSell5,000$57.03$285,150.00 8/12/2024B Lynne ParshallDirectorSell5,000$55.20$276,000.00 8/12/2024Robert I BlumCEOSell11,500$55.17$634,455.00 (Data available from 1/1/2013 forward) CYTK Insider Trading Activity - Frequently Asked Questions Who is on Cytokinetics' Insider Roster? The list of insiders at Cytokinetics includes Andrew Callos, B Lynne Parshall, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, Muna Bhanji, Robert Arthur Harrington, Robert I Blum, Robert Wong, and Wendall Wierenga. Learn more on insiders at CYTK. What percentage of Cytokinetics stock is owned by insiders? 2.70% of Cytokinetics stock is owned by insiders. Learn more on CYTK's insider holdings. Which Cytokinetics insiders have been selling company stock? The following insiders have sold CYTK shares in the last 24 months: Andrew Callos ($799,708.37), B Lynne Parshall ($1,388,150.00), Edward M Md Kaye ($116,715.60), Fady Ibraham Malik ($15,226,585.42), John T Henderson ($1,702,844.48), Muna Bhanji ($147,367.42), Robert Arthur Harrington ($108,411.03), Robert I Blum ($15,404,345.04), Robert Wong ($635,977.68), and Wendall Wierenga ($1,966,646.02). How much insider selling is happening at Cytokinetics? Insiders have sold a total of 696,264 Cytokinetics shares in the last 24 months for a total of $37,496,751.06 sold. Cytokinetics Key ExecutivesMr. Robert I. Blum (Age 60)President and Chief Executive Officer Compensation: $1.33M9 recent tradesMr. Robert C. Wong (Age 56)VP & Chief Accounting Officer Compensation: $495.72kDr. Fady Ibraham Malik FACC (Age 60)M.D., Ph.D., Executive Vice President of Research & Development Compensation: $839.66kMr. Andrew M. Callos (Age 55)Executive VP & Chief Commercial Officer Compensation: $752.84k6 recent tradesDr. James A. Spudich Ph.D. (Age 82)Co-Founder & Member of Scientific Advisory Board Compensation: $21.94kMr. Jeff LotzVice President of Sales & OperationsMr. Matt YangVice President of Corporate Finance and Financial Planning & AnalysisMr. Steven M. Cook (Age 65)Senior Vice President of Global Supply Chain Operations & Technical Operations Ms. Kari K. Loeser J.D.VP & Chief Compliance OfficerMr. John O. Faurescu Esq.VP, Associate General Counsel & Corporate Secretary More Insider Trading Tools from MarketBeat Related Companies GMAB Insider Transactions MRNA Insider Transactions VTRS Insider Transactions VRNA Insider Transactions BBIO Insider Transactions BPMC Insider Transactions ROIV Insider Transactions ELAN Insider Transactions RVMD Insider Transactions GRFS Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:CYTK) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
